Lectin Superfamily TRIZ Cases
- Genetically Modified Cells for NK-Mediated Immune Evasion
Engineered cells express CLEC2D, TRAIL, and SERPINB9 to reduce natural killer cytotoxicity, helping allogeneic therapies resist rejection with less immunosuppression.
- Genetically Engineered Cells Resist Natural Killer Cytotoxicity
CLEC2D, TRAIL, and SERPINB9 expression helps engineered cells resist natural killer cytotoxicity and support allogeneic cell survival.
- PEGylated Glycopeptides Inhibit P-Selectin to Reduce Bleeding Risk
PEGylated glycopeptides block P-selectin to prevent venous thrombus formation without increasing bleeding risk.
- PEGylated Gal3C Protein Thermal Unfolding Pathway Redirection
Covalent PEG attachment redirects the thermal unfolding pathway of Gal3C, resolving unpredictable stability outcomes from arbitrary protein modification.
- Radioconjugated NKG2DL Agents for Tumor Reduction
Radioconjugated agents deliver DNA-damaging radiation to cancer cells expressing NKG2D ligands, overcoming CAR T cell persistence limits.
- Transgenic Mice Expressing Human Siglec Proteins
Transgenic mice expressing human Siglec proteins overcome evolutionary divergence in animal models for disease research.
- Chimeric NKG2D Protein for Full T-Cell Activation
A chimeric NKG2D protein combines human extracellular and murine transmembrane domains to associate with adaptor proteins.